Maintenance Therapy Duration and Considerations for Treatment Interruption

Video

Experts comment on the typical urothelial cancer maintenance therapy duration in their practice, and situations in which they might consider interrupting treatment while maintaining patient response.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions and subtitles off, selected
      Recent Videos
      Managing Epithelioid Sarcoma: Follow-Up Strategies and Treatment Decisions for Stable Disease vs Progression
      Managing Epithelioid Sarcoma: Follow-Up Strategies and Treatment Decisions for Stable Disease vs Progression
      Navigating Frontline Therapy in Epithelioid Sarcoma: Key Clinical Considerations and Shared Decision-Making
      Navigating Frontline Therapy in Epithelioid Sarcoma: Key Clinical Considerations and Shared Decision-Making
      Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
      Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
      Institutional Implementation: Setting Up Tarlatamab Administration
      Institutional Implementation: Setting Up Tarlatamab Administration
      TAR-200 Might Be “Best in Class” for BCG-Unresponsive High-Risk NMIBC
      TAR-200 Might Be “Best in Class” for BCG-Unresponsive High-Risk NMIBC
      Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
      Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
      Expert Perspectives: Tazemetostat in R/R FL
      Expert Perspectives: Tazemetostat in R/R FL
      Management Strategies for Localized Epithelioid Sarcoma: The Role of Neoadjuvant and Adjuvant Therapies
      Management Strategies for Localized Epithelioid Sarcoma: The Role of Neoadjuvant and Adjuvant Therapies
      4 experts in this video
      Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
      4 experts in this video
      Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
      Related Content
      Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

      Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

      Roman Fabbricatore
      May 9th 2025
      Article

      Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

      NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

      NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
      March 4th 2025
      Podcast

      The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

      FDA Issues Refusal to File Letter for Nogapendekin Alfa Inbakicept in NMIBC

      FDA Issues Refusal to File Letter for Nogapendekin Alfa Inbakicept in NMIBC

      Tim Cortese
      May 5th 2025
      Article

      The FDA refuses to file the sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with papillary disease without carcinoma in situ.

      Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

      Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

      Matthew Fowler;Jun Gong, MD
      March 15th 2022
      Podcast

      Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

      TAR-200 Improves Survival in BCG-Unresponsive, Papillary High-Risk NMIBC

      TAR-200 Improves Survival in BCG-Unresponsive, Papillary High-Risk NMIBC

      Chris Ryan
      May 2nd 2025
      Article

      Data from cohort 4 of the phase 2 SunRISe-1 trial demonstrate durable DFS with TAR-200 in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.

      Nogapendekin Alfa Inbakicept Elicits Promising Efficacy in Bladder Carcinoma

      Nogapendekin Alfa Inbakicept Elicits Promising Efficacy in Bladder Carcinoma

      Tony Berberabe, MPH
      May 1st 2025
      Article

      Nogapendekin alfa inbakicept plus BCG led to a CR rate of 71%, with 60% of responders maintaining their response for at least 12 months, in patients with bladder carcinoma in situ.